The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
Open accessAbstract
Background: We conducted a phase II multi-center trial of induction chemotherapy followed by response-adapted, dose-reduced radiation therapy with radiosensitizing chemotherapy for patients with locally advanced, human papillomavirus (HPV)-associated squamous cell carcinoma of the oropharynx. The aim of this study was to determine the progression-free survival for patients treated using this de-escalated approach to determine its worthiness for further investigation in a phase III setting. Methods: Eligible patients presented with newly diagnosed, biopsy-proven stage III or IV squamous cell carcinoma of the oropharynx, p16-positivity, and Zubrod performance status 0 to 1. Smoking history was not used as a criterion for eligibility. Treatment was induction paclitaxel 175 mg/m2 and carboplatin area under the concentration-time curve (AUC) 6 for two cycles every 21 days followed by dose-reduced radiation of 54 Gy or 60 Gy for responders and non-responders, respectively, with weekly paclitaxel 30 mg/m2. Intensity-modulated radiotherapy with daily image-guidance was required. The primary endpoint was 2-year progression-free survival as determined by per protocol analysis. This study is registered with ClinicalTrials.gov, numbers NCT02048020 and NCT01716195. Findings: Between October 4, 2012 and March 3, 2015, forty-five patients (26 tonsil; 19 base of tongue) were registered, of which 44 were analyzable. Median age was 60 years old (IQR, 54 to 67). Sixty-nine percent of the patients were lifelong never smokers. Twenty-four patients (55%) exhibited a complete or partial response to induction chemotherapy; twenty patients (45%) had a less than partial response to induction chemotherapy. With a median follow up of 30 months (IQR, 26 to 37 months), three (7%) of 44 patients developed local-regional recurrence and another distant metastasis, yielding a 2-year progression-free survival of 92%. The most commonly observed grade 3+ toxicity was leukopenia (17 patients) with the most common grade 3+ non-hematologic toxicities being dysphagia (4 patients) and mucositis (4 patients). Seventeen (39%) of 44 patients and nine (20%) of 44 patients developed any grade 3+ and non-hematologic grade 3+ toxicity, respectively, during protocol therapy.. The proportion who were gastrostomy-tube dependent at 3- and 6-months post-therapy was 2% (1 of 44 patients) and 0%, respectively. Interpretation: The rates of disease control demonstrated with this de-escalation regimen for patients with locally advanced, HPV-associated oropharyngeal carcinoma were comparable to those of historical controls treated by standard dose chemoradiotherapy regimens. Additionally, long-term side effects appeared to be reduced. By decreasing toxicity while maintaining cure rates, de-escalation of radiation dose has the potential to improve the therapeutic ratio and optimize long-term function for patients with a disease that is rapidly increasing in incidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Fakhry, C., Westra, W. H., Li, S., Cmelak, A., Ridge, J. A., Pinto, H., Forastiere, A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,779
Gillison, M. L., D'Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn025 · Cited by 1,543
Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers
Chaturvedi, A. K., Anderson, W. F., Lortet-Tieulent, J., Curado, M. P., Ferlay, J., Franceschi, S., Rosenberg, P. S., Bray, F., & Gillison, M. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3870 · Cited by 1,293
Ang, K. K., Zhang, Q., Rosenthal, D. I., Nguyen-Tan, P. F., Sherman, E. J., Weber, R. S., Galvin, J. M., Bonner, J. A., Harris, J., El-Naggar, A. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5633 · Cited by 838
Weinberger, P. M., Yu, Z., Haffty, B. G., Kowalski, D., Harigopal, M., Brandsma, J., Sasaki, C., Joe, J., Camp, R. L., Rimm, D. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.3335 · Cited by 796
O'Sullivan, B., Huang, S. H., Su, J., Garden, A. S., Sturgis, E. M., Dahlstrom, K., Lee, N., Riaz, N., Pei, X., Koyfman, S. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00560-4 · Cited by 750
Cited by
Head and neck squamous cell carcinoma
Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00224-3 · Cited by 4,067
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Lechner, M., Liu, J., Masterson, L., & Fenton, T. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00603-7 · Cited by 979
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Caudell, J. J., Gillison, M. L., Maghami, E., Spencer, S., Pfister, D. G., Adkins, D., Birkeland, A. C., Brizel, D. M., Busse, P. M., Cmelak, A. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0016 · Cited by 526
A Review of HPV-Related Head and Neck Cancer
Kobayashi, K., Hisamatsu, K., Suzui, N., Hara, A., Tomita, H., & Miyazaki, T. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090241 · Cited by 282
Metadata
- Authors
- Chen, A. M., Felix, C., Wang, P.-C., Hsu, S., Basehart, V., Garst, J., Beron, P., Wong, D., Rosove, M. H., Rao, S., Melanson, H., Kim, E., Palmer, D., Qi, L., Kelly, K., Steinberg, M. L., Kupelian, P. A., & Daly, M. E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 18
- Issue
- 6
- Pages
- 803-811
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2607491790
- Cited by
- 326
- References
- 29
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(17)30246-2
- The paper
- Chen, A. M., Felix, C., Wang, P.-C., Hsu, S., Basehart, V., Garst, J., Beron, P., Wong, D., Rosove, M. H., Rao, S., Melanson, H., Kim, E., Palmer, D., Qi, L., Kelly, K., Steinberg, M. L., Kupelian, P. A., & Daly, M. E. (2017). Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(17)30246-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.